Whilst retaining designation as a CD8-positive lesion of acral sites, the 2022ICC preferred to revert to calling this entity a lymphoproliferative disorder in view of its indolent behaviour, and in keeping with a trend to more conservative use of nomenclature across categories. This evidence concerns the gene CD8A and lymphoproliferative syndrome.